Transarterial Chemoembolization with Drug-eluting Beads in Hepatocellular Carcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2016 Nov 12

PMID 27833376

Citations 16

Authors

Hee Chul Nam

Bohyun Jang

Myeong Jun Song

Affiliations

Soon will be listed here.

Abstract

Transarterial chemoembolization (TACE) is a widely used standard treatment for patients with hepatocellular carcinoma (HCC) who are not suitable candidates for curative treatments. The rationale for TACE is that intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, followed by selective vascular embolization, results in a strong cytotoxic effect as well as ischemia (conventional TACE). Recently, drug-eluting beads (DC Beads) have been developed for transcatheter treatment of HCC to deliver higher doses of the chemotherapeutic agent and to prolong contact time with the tumor. DC Beads can actively sequester doxorubicin hydrochloride from solution and release it in a controlled sustained fashion. Treatment with DC Beads substantially reduced the amount of chemotherapeutic agent that reached the systemic circulation compared with conventional, lipiodol-based regimens, significantly reducing drug-related adverse events. In this article, we describe the treatment response, survival, and safety of TACE used with drug-eluting beads for the treatment of HCC and discuss future therapeutic possibilities.

Citing Articles

Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis.

Chen Y, Huang C, Li C, Chang T, Su W, Chen P World J Surg Oncol. 2023; 21(1):378.

PMID: 38041083 PMC: 10691074. DOI: 10.1186/s12957-023-03253-w.

Transcatheter embolization of hepatocellular carcinoma with epirubicin-loaded DC beads in Chinese patients.

Zhou G, Sun J, Zhang Y, Zhou T, Nie C, Zhu T Transl Cancer Res. 2022; 8(1):279-289.

PMID: 35116757 PMC: 8799907. DOI: 10.21037/tcr.2019.01.36.

Translational Development of a Silk-Elastinlike Protein Polymer Embolic for Transcatheter Arterial Embolization.

Hatlevik O, Jensen M, Steinhauff D, Wei X, Huo E, Jedrzkiewicz J Macromol Biosci. 2022; 22(2):e2100401.

PMID: 34978152 PMC: 9007042. DOI: 10.1002/mabi.202100401.

Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma.

Razi M, Jianping G, Xu H, Ahmed M J Interv Med. 2021; 4(1):11-14.

PMID: 34805941 PMC: 8562211. DOI: 10.1016/j.jimed.2020.10.006.

Traditional versus Microsphere Embolization for Hepatocellular Carcinoma: An Effectiveness Evaluation Using Data Mining.

Chang P, Cheng C, Hon J, Kuo C, Yen C, Chai J Healthcare (Basel). 2021; 9(8).

PMID: 34442066 PMC: 8392597. DOI: 10.3390/healthcare9080929.

References

Victoria Gonzalez M, Tang Y, Phillips G, Lloyd A, Hall B, Stratford P . Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation. J Mater Sci Mater Med. 2007; 19(2):767-75. DOI: 10.1007/s10856-006-0040-y. View

Chung W, Lee K, Park M, Lee Y, Kwon J, Baek S . Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. AJR Am J Roentgenol. 2012; 199(2):349-59. DOI: 10.2214/AJR.11.7563. View

Han S, Zhang X, Zou L, Lu C, Zhang J, Li J . Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PLoS One. 2014; 9(8):e102686. PMC: 4118844. DOI: 10.1371/journal.pone.0102686. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A . Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2009; 33(1):41-52. PMC: 2816794. DOI: 10.1007/s00270-009-9711-7. View

Kobayashi S, Nakanuma Y, Matsui O . Intrahepatic peribiliary vascular plexus in various hepatobiliary diseases: a histological survey. Hum Pathol. 1994; 25(9):940-6. DOI: 10.1016/0046-8177(94)90016-7. View

Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S . Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging. 2007; 33(5):512-9. DOI: 10.1007/s00261-007-9334-x. View

Spreafico C, Cascella T, Facciorusso A, Sposito C, Rodolfo L, Morosi C . Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. Cardiovasc Intervent Radiol. 2014; 38(1):129-34. DOI: 10.1007/s00270-014-0907-0. View

Facciorusso A, Mariani L, Sposito C, Spreafico C, Bongini M, Morosi C . Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2015; 31(3):645-53. DOI: 10.1111/jgh.13147. View

10.

Parkin D, Bray F, Ferlay J, Pisani P . Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2):153-6. DOI: 10.1002/ijc.1440. View

11.

Lee J, Won J, Park S, Won J, Lee D, Kang B . Transcatheter arterial chemoembolization of hepatocellular carcinoma with hepatic arteriovenous shunt after temporary balloon occlusion of hepatic vein. J Vasc Interv Radiol. 2007; 18(3):377-82. DOI: 10.1016/j.jvir.2007.01.005. View

12.

Malagari K . Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther. 2008; 8(10):1643-50. DOI: 10.1586/14737140.8.10.1643. View

13.

Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V . Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol. 2011; 56(3):609-17. DOI: 10.1016/j.jhep.2011.09.012. View

14.

Song M, Chun H, Song D, Kim H, Yoo S, Park C . Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012; 57(6):1244-50. DOI: 10.1016/j.jhep.2012.07.017. View

15.

Angelico M . TACE vs DEB-TACE: Who wins?. Dig Liver Dis. 2016; 48(7):796-7. DOI: 10.1016/j.dld.2016.05.009. View

16.

Namur J, Citron S, Sellers M, Dupuis M, Wassef M, Manfait M . Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol. 2011; 55(6):1332-8. DOI: 10.1016/j.jhep.2011.03.024. View

17.

Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35(3):421-30. DOI: 10.1016/s0168-8278(01)00130-1. View

18.

Cucchetti A, Trevisani F, Cappelli A, Mosconi C, Renzulli M, Pinna A . Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis. 2016; 48(7):798-805. DOI: 10.1016/j.dld.2016.03.031. View

19.

Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S . Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2007; 31(2):269-80. DOI: 10.1007/s00270-007-9226-z. View

20.

Song M, Park C, Kim J, Kim H, Bae S, Choi J . Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol. 2011; 23(6):521-7. DOI: 10.1097/MEG.0b013e328346d505. View